Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients

A 6-Week, Multi-centre, Double-blind, Double-dummy, Chlorpromazine-Controlled Randomised Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Extended-Release in the Treatment of Schizophrenic Patients With Acute Episode

The primary objective of this study is to evaluate the efficacy of quetiapine fumarate extended-release (XR) used as mono-therapy, administered once daily, in the treatment of schizophrenic patient with acute episode.

Inclusion Criteria:

• Schizophrenia diagnosis
• Provision of written informed consent before initiation of any study

Exclusion Criteria:

• AIDS and hepatitis B
• History of seizure disorder
• Hospitalisation for schizophrenic more than 1 month immediately before enter into study